Stevanato Group S.p.A (STVN) Cash from Investing Activities (2020 - 2026)
Stevanato Group S.p.A's (STVN) quarterly Cash from Investing Activities came in at -$82.4 million in Q1 2026, down 10.81% year-on-year from -$92.4 million in Q1 2025, and up 24.96% on a QoQ basis from -$109.8 million in Q4 2025.
Stevanato Group S.p.A (STVN) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Stevanato Group S.p.A (STVN) has 7 years of Cash from Investing Activities data on file, last reported at -$82.4 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 10.81% year-over-year to -$82.4 million in Q1 2026; TTM through Mar 2026 was -$316.1 million, a 5.82% decrease from a year earlier, with the FY2025 full-year figure at -$317.7 million, up 4.16% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$82.4 million, up from -$109.8 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for STVN reached as high as -$43.6 million in Q3 2022 and fell as low as -$143.9 million in Q3 2023.
- Historically, Cash from Investing Activities has averaged -$85.5 million across 5 years, with a median of -$81.3 million in 2022.
- Across the five-year window, Cash from Investing Activities tumbled 230.4% in 2023 and jumped 63.7% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$70.2 million in 2022, then slumped by 41.45% to -$99.3 million in 2023, then increased by 2.03% to -$97.3 million in 2024, then retreated by 12.91% to -$109.8 million in 2025, then increased by 24.96% to -$82.4 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$82.4 million in Q1 2026, -$109.8 million in Q4 2025, and -$56.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.54 Bn | 121.33 Bn | 1.96 Bn | -26.60 Mn |
| 2 | Becton Dickinson | 44.82 Bn | 44.00 Bn | 2.15 Bn | -139.00 Mn |
| 3 | Alcon | 32.93 Bn | 31.28 Bn | 1.53 Bn | -218.00 Mn |
| 4 | Medline | 32.92 Bn | 30.68 Bn | 1.84 Bn | -96.00 Mn |
| 5 | Resmed | 29.48 Bn | 27.82 Bn | 890.98 Mn | -58.03 Mn |
| 6 | West Pharmaceutical Services | 23.40 Bn | 22.97 Bn | 329.20 Mn | -43.20 Mn |
| 7 | Solventum | 14.04 Bn | 13.48 Bn | 1.10 Bn | -77.00 Mn |
| 8 | Cooper Companies | 13.79 Bn | 13.65 Bn | 735.40 Mn | -90.00 Mn |
| 9 | Align Technology | 12.05 Bn | 10.99 Bn | 736.59 Mn | -131.58 Mn |
| 10 | Stevanato Group S.p.A | 5.43 Bn | 5.28 Bn | 88.01 Mn | -82.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82.42 Mn |
| Mar 31, 2026 | -82.42 Mn |
| Dec 31, 2025 | -109.83 Mn |
| Dec 31, 2025 | -109.83 Mn |
| Sep 30, 2025 | -56.34 Mn |
| Sep 30, 2025 | -56.34 Mn |
| Jun 30, 2025 | -67.53 Mn |
| Jun 30, 2025 | -67.53 Mn |
| Mar 31, 2025 | -74.38 Mn |
| Mar 31, 2025 | -74.38 Mn |
| Dec 31, 2024 | -97.28 Mn |
| Dec 31, 2024 | -97.28 Mn |
| Sep 30, 2024 | -52.24 Mn |
| Sep 30, 2024 | -52.24 Mn |
| Jun 30, 2024 | -74.84 Mn |
| Jun 30, 2024 | -74.84 Mn |
| Mar 31, 2024 | -110.93 Mn |
| Mar 31, 2024 | -110.93 Mn |
| Dec 31, 2023 | -99.29 Mn |
| Dec 31, 2023 | -99.29 Mn |